PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...
Conducted in 148 centers in Canada, New Zealand, and the United States between September 1997 and July 2001, SCD-HeFT involved a total of 2521 patients with dilated cardiomyopathy, with or without ...
Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) were associated with improved left ventricular diastolic function and New York Heart Association (NYHA) class in patients with hypertrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results